BRD4 and neoplasm: The landmark discovery of the BRD4-NUTM1 fusion gene in two independent cell lines derived from these carcinomas in 2003 provided for the genetic causality [8], which was further corroborated by functional characterization of NUTM1 fusions such as BRD4-NUTM1 [9], BRD3-NUTM1 [9], and NSD3-NUTM1 [10], and genomic sequencing showing a low tumor mutational burden (TMB) and lack of other oncogenic drivers [11].